Anterior Migration of Intravitreal Fluocinolone Acetonide Implants: A Case Report

Gunzenhauser, Robert; Greven, Margaret A.; John, Vishak J.

doi:10.1097/icb.0000000000000897

Cited by 7 publications

(1 citation statement)

References 7 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FAi is smaller than the dexamethasone implant (3.5 vs 6 mm in length, respectively), 34,35 and can migrate through an even smaller opening and potentially cause corneal edema. 36 Dr Kiernan: I usually start with the dexamethasone implant and switch as needed to the 0.18-mg FAi. When I use the 0.18-mg FAi, I examine patients 1 month later to assess efficacy in terms of leakage and IOP.…”

Section: Role Of the Long-term 018-mg Fluocinolone Acetonide Intravit...mentioning

confidence: 99%

Is It Uveitis? Identifying and Managing Challenging Cases in Chronic Postsurgical Inflammation

2022

Retina

View full text Add to dashboard Cite

Posterior segment ocular inflammation (uveitis) is a common complication of ocular surgery that can lead to cystoid macular edema and poor visual outcomes. Management of posterior segment inflammation often consists of repeated treatments of topical, systemic, or intravitreal corticosteroids. These approaches can have drawbacks of duration, safety, and burden. Novel treatment options are now available to expand the therapeutic armamentarium for the management of chronic postoperative inflammation. This educational activity aims to educate retina specialists and other ophthalmologists on postsurgical uveitis, including current evidence-based treatments and strategies for incorporating best practices into patient care. The desired results of this activity are for retina specialists and other ophthalmologists to recognize postoperative chronic posterior segment inflammation (uveitis) as part of the spectrum of uveitides and to select treatments that balance safety and efficacy. TARGET AUDIENCEThis educational activity is intended for retina specialists and other ophthalmologists. LEARNING OBJECTIVESAfter completing this activity, participants will be better able to: • Describe evidence-based treatments for posterior segment inflammation (uveitis) and cystoid macular edema following ocular surgery • Design treatment plans for posterior segment inflammation (uveitis) and cystoid macular edema that balance safety and efficacy following ocular surgery ACCREDITATION STATEMENTMedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENTMedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. INSTRUCTIONS FOR OBTAINING CREDITTo obtain AMA PRA Category 1 Credit™ for this activity, please read the monograph, consult referenced sources as necessary, and complete the posttest and evaluation online at https://tinyurl.com/PSuveitis. Upon passing, a certificate will be made available immediately. DISCLOSURE POLICYMedEdicus adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

show abstract

Section: Role Of the Long-term 018-mg Fluocinolone Acetonide Intravit...mentioning

confidence: 99%